Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 15, 2025BDJOpen Access

Remimazolam besylate in intravenous conscious sedation for dental treatment: a prospective cohort study

View Full Paper
Ask AI
Bookmark
Share

Authors

GGGiovanni Battista GrossiGMGregorio MenozziCMCarlo Maiorana

Discussion

Loading...

Member takes

Overview

Prospective cohort study reveals remimazolam's efficacy and safety in dental sedation, highlighting high patient satisfaction and rapid recovery.

Key Points

  • Remimazolam achieved a 100% procedural success rate in dental sedation, indicating its high efficacy and safety.
  • 69% of patients reported significant anxiety reduction, demonstrating remimazolam's effective anxiolytic properties in dental settings.
  • This prospective cohort study with 101 patients assessed various outcomes, including sedation depth and psychomotor recovery post-treatment.
  • Remimazolam's minimal adverse effects and high patient satisfaction indicate its potential as an alternative to midazolam for sedation.

Cite This Study

Grossi et al. (2025) studied this question.

synapsesocial.com/papers/68af2b68cf1dd9ea359e4d25https://doi.org/10.1038/s41415-025-8664-9
View Full Paper
Ask AI
Bookmark
Share